Research Studies

Leukemia and Lymphoma Program Research Studies

Find research studies available to children cared for by the Leukemia and Lymphoma Program team.
Existing patients or family members
New patients, referrals and second opinions

Search Research Studies

Clinical trial
Children (5)
Adults (2)

Clinical Trial Phases
Phase I (4)
Phase II (4)

Recruitment Status
Recruiting (3)
Non-recruiting (2)

Related conditions
Desmoid tumors (1)
Ewing sarcoma (1)
Hepatoblastoma (liver cancer) (1)
Non-Hodgkin Lymphoma in Children (1)
Osteosarcoma (bone cancer in children) (1)
Wilms Tumor (Kidney Tumor) (1)

Related Specialties and Programs
Leukemia and Lymphoma Program (5)
Cancer Center (4)
Relapsed Leukemia and Lymphoma Program (3)
Center for Precision Medicine for High-Risk Pediatric Cancer (1)
Solid Tumor Program (1)

Specialty
Oncology (5)

AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia
This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R). The KMT2A-R leukemia has come back after treatment (relapsed) or is not responding to treatment (it is refractory). This study involves taking a study drug called SNDX-5613. The study is divided into two phases: one in which the study drug is given in combination with chemotherapy and a phase where the study drug is given alone. The purpose of the study is to test the safety of the study drug with chemotherapy, and how well the treatment regimen works for infants and young children with relapsed or refractory KMT2A-R leukemia.

Phase: Phase II

Actively recruiting: Yes

Category: Children

Allo CD7 CAR WU-CART-007

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as WU-CART-007 ("study drug"). WU-CART-007 uses immune cells, called T cells, that are genetically changed to identify cancer cells. In this study, T cells are collected from a healthy human donor and have been modified in a laboratory. If the genetically changed T cells recognize and attach to cancer cells, they may have the ability to kill those cancer cells.

Patients with T-cell Acute Lymphoblatic Leukemia (T-ALL) or Lymphoblastic Lymphoma (LBL), where the disease has come back (relapsed) or has not responded to treatment (refractory) may be eligible for the study.

Phase: Phase I, Phase II

Actively recruiting: No

Category: Adults, Children

Oral Asciminib in CML

This study involves taking a study drug called asciminib. The overall goal of the study is to find out how safe and effective the study drug is in treating people that have been diagnosed with Chronic Myeloid Leukemia (CML) and have not responded to treatment.

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Children

Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids
This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory"). Part B enrolls patients with a relapsed or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor, Wilms tumor, or tumors with changes in a gene family known as the Wnt pathway. This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose. 

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Adults, Children

Conditions: Desmoid tumors , Ewing sarcoma, Hepatoblastoma (liver cancer), Non-Hodgkin Lymphoma in Children, Osteosarcoma (bone cancer in children), Wilms Tumor (Kidney Tumor)

Uproleselan in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Mixed Phenotype Acute Leukemia (MPAL)
This study enrolls patients that have been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or mixed phenotype acute leukemia (MPAL) that has either come back (‘relapsed’) or does not respond to therapy (‘refractory’). This study involves taking a drug called uproleselan that is not yet approved for use in children or adults. The purpose of the study is to find a safe dose of the study drug in children that can be given with standard chemotherapy without causing severe side effects. 

Phase: Phase I

Actively recruiting: No

Category: Children